Kyprolis is a cancer medicine used together with the medicines daratumumab and dexamethasone, or lenalidomide and dexamethasone or with dexamethasone alone, to treat multiple myeloma (a cancer of the bone marrow). It is given to adults who have received at least one previous treatment for their cancer. Kyprolis contains the active substance carfilzomib. Multiple myeloma is rare, and Kyprolis was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 3 June 2008\.
Therapeutic Indication
Kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Therapeutic Area (MeSH)
ATC Code
L01XX45
ATC Item
N/A
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
EMA Name
Kyprolis
Medicine Name
Kyprolis
Aliases
N/ANo risk management plan link.
